United Therapeutics Corp(UTHR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 18.02 | EPS (ttm) | 27.96 | Insider Own | 3.35% | Shs Outstand | 42.7M | Perf Week | 2.41% |
| Market Cap | 21.61B | Forward P/E | 17.43 | EPS next Y | 10.53% | Insider Trans | -51.98% | Shs Float | 41.5M | Perf Month | -2.26% |
| Enterprise Value | 18.95B | PEG | 2.31 | EPS next Q | 6.44 | Inst Own | 97.47% | Short Float | 5.1% | Perf Quarter | -7.4% |
| Income | 1.31B | P/S | 6.85 | EPS this Y | -6.15% | Inst Trans | -1.31% | Short Ratio | 4.06 | Perf Half Y | -7.5% |
| Sales | 3.15B | P/B | 3.36 | EPS next 5Y | 7.56% | ROA | 17.33% | Short Interest | 2.11M | Perf YTD | 3.41% |
| Book/sh | 149.97 | P/C | 8.12 | EPS past 3/5Y | 22.94% 19.27% | ROE | 19.32% | 52W High | -17.31% ($609.35) | Perf Year | 27.08% |
| Cash/sh | 62.07 | P/FCF | 19.83 | Sales past 3/5Y | 18.02% 16.5% | ROIC | 20.48% | 52W Low | 27.56% ($395.00) | Perf 3Y | 123.81% |
| Dividend Est. | - | EV/EBITDA | 12.68 | EPS Y/Y TTM | 9.29% | Gross Margin | 86.14% | Volatility(W/M) | 4.23% 2.83% | Perf 5Y | 139.64% |
| Dividend TTM | - | EV/Sales | 6.01 | Sales Y/Y TTM | 2.49% | Oper. Margin | 44.49% | ATR (14) | 14.9 | Perf 10Y | 320.02% |
| Dividend Ex-Date | - | Quick Ratio | 5.41 | EPS Q/Q | 13.46% | Profit Margin | 41.56% | RSI (14) | 45.35 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.73 | Sales Q/Q | -1.92% | SMA20 | -1.05% ($509.21) | Beta | 0.5 | Target Price | $664.33 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/5 | SMA50 | -3.71% ($523.27) | Rel Volume | 0.84 | Prev Close | $506.82 |
| Employees | 1400 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 5.95% -2.65% | SMA200 | -3.82% ($523.87) | Avg Volume(3M) | 0.52M | Price | $503.86 |
| IPO | 1999/6/17 | Option/Short | Yes/Yes | Trades | 12623 | Volume | 439,152 | Change | -0.58% |
Company
UTHR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A U.S. specialty pharmaceutical company whose core asset is a treprostinil-based therapy for pulmonary arterial hypertension. It holds a portfolio of inhaled, intravenous, and oral formulations, along with an innovative pipeline that includes next-generation inhalers and implanted devices, making it a rare disease therapeutics specialist.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
UTHR makes money exceptionally well
44.49% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -6.2% this year.
Tap to view numbers
The price looks about right
Trading at 18.0 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +123.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 97.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PINK 0.07%
PBE 0.06%
LFSC 0.04%
XMHQ 0.04%
GLRY 0.04%It ranks #4 in the industry
Based on market cap of $22B.
UTHR $22B PER 18.0
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is UTHR?
UTHR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of UTHR?
The market cap of UTHR is approximately $21.6B, ranking 582 within its sector.
What is the P/E ratio of UTHR?
UTHR has a P/E ratio of approximately 18.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for UTHR?
UTHR has recorded a 52-week high of $609.35 and a low of $395.00.
